AmpliPhi granted Japanese patent covering the use of phage therapy to resensitize Pseudomonas aeruginosa infections to antibiotics
AB-PA01 designed to broadly target both CF and non-CF Pseudomonas isolates and potentially eradicate the infection instead of merely keeping it at bay.
AmpliPhi Biosciences has announced that the Japanese Patent Office has granted AmpliPhi a patent for the “Beneficial effects of bacteriophage treatments” targeting Pseudomonas aeruginosa (Pseudomonas) infections. A corresponding patent has been granted in the US and is currently being prosecuted in Canada. Additional patents with broader bacterial species claims have been granted in the European Union and Australia.
The patent covers the treatment of Pseudomonas infections through the sequential use of a bacteriophage (phage) therapeutic followed by an antibiotic to which the bacteria were formerly resistant. During the first stage of phage administration, antibiotic-resistant Pseudomonas are placed under extreme selective pressure by the attacking phage. Following the initial assault, most of the bacteria die, but a small portion may evade the phage attack by mutating in a way that protects them from the phage but at the same time resensitizes that population to antibiotics. Antibiotics are then administered to deplete the remaining bacterial population. This resensitization phenomenon has been observed in both in vitro and in vivo experiments, as well as in a few antibiotic-resistant human infections, including a previously-reported case where an antibiotic-resistant Pseudomonas bladder infection was treated and cleared in Australia under a compassionate use exemption.
Pseudomonas infects almost 60% of cystic fibrosis (CF) patients overall, with approximately 80% of patients over the age of 18 chronically infected by the pathogenic bacteria. Recurrent Pseudomonas infections cause severe lung damage and can lead to bronchiectasis and the need for lung transplants. Current standard of care treatment for CF patients include inhaled antibiotics that tamp down but may not eliminate the infection. AmpliPhi’s investigational drug therapy, AB-PA01, is designed to broadly target both CF and non-CF Pseudomonas isolates and potentially eradicate the infection instead of merely keeping it at bay.
“Through a step-wise treatment paradigm of AB-PA01 followed by antibiotics, we envision a treatment modality that effectively clears chronic Pseudomonas infections in CF patients,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “By resensitizing Pseudomonas to antibiotics, we can turn back the clock on currently ineffective antibiotics and make them relevant again. Antibiotic resensitization has the potential to provide patients and caregivers with a new set of weapons to make impactful progress against the growing threat of antibiotic resistance by combining the natural ability of phage to selectively target bacteria with the current arsenal of antibiotics. We look forward to evaluating our proprietary phage cocktail alongside existing antibiotics to address recurrent and resistant Pseudomonas infections in patients with CF.”
AB-PA01 is currently being manufactured in AmpliPhi’s cGMP facility and is in nonclinical studies at the Royal Brompton Hospital, London, UK. AmpliPhi anticipates initiating a Phase 1 clinical trial in 2017 of AB-PA01 for the treatment of CF using a nebulized formulation of the phage cocktail.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance